孟鲁司特钠有效治疗慢性阻塞性肺疾病临床疗效观察.doc

孟鲁司特钠治疗慢性阻塞性肺疾病临床疗效观察孟鲁司特钠治疗慢性阻塞性肺疾病临床疗效观察?86?专用临医药蛩志2o?年第15卷第7期Jouma1ofClinicalMedicineinPractice..…'孟鲁司特钠治疗慢性阻塞性肺疾病临床疗效观察刘金丽,唐颖,李佳,尚晓霞,银翠荣,何平,鹿翠香(黑龙江省大庆市油田总医院集团龙南医院呼吸内科,黑龙江大庆,163001)摘要:(=26)及对照组(,z=24).对照组给予静脉抗感染,止咳,化痰,平喘,吸氧等对症治疗;治疗组在对照组基础七加用盂鲁司特钠10n-~/d,,对照组治疗后第一秒末用力呼气量(FEV1)百分比和用力肺活量(FEVl/FVC)百分比无明显差异,治疗组FEv(%)和FEV1/FVC(%)治疗后明显上升,与治疗前比较差异有统计学意义(P<).冶疗前比较,两组患者治疗后Pa02水平明显升高,PaC02水平明显降低,差异有统计学意义(P<);与对照组比较,治疗组治疗后PaO,升高及PaCO2降低水平更明显(P<).:慢性阻塞性肺疾病;孟鲁司特钠中图分类号:R563文献标志码:A文章编号:1672—2353(20l1)070086—02Theclinical0bservati0nofMontelukastSodiuminthetreatmentofchronicobstructivepulmonarydiseaseLIUJin—li,TANGYing,LIJia,SHANGXiao,xia,YINCui—rong,HEPing,LUCui—xiang(LongnanHospitalofDaqingOilfieldGeneralHospitalGroup,Daqing,Heilongjiang,163001)ABSTRACT:ObjectiveToexploretheroleofMontelukastSodiuminthetreatmentofchron——easewererandomlydividedintotreatmentgroup(=26)andcontrolgroup(=24).Controlgroupwasgivenintravenousantibiotics,coughandphlegm,asthma,oxygenandothersymptomatictreatment,thetreatmentgroupreceivedadditionalservicesonthebasisofMontelukastSodiumtablets10mg/d,—treatmentandpost—treatment,thereisnosignificantdifferenceofFEV1%andFEV1/FVC%paredwithpre—treatment,posttreatmentthereissignificantdifferenceofFFV1/FVC%andFEV1%inthetreatmentgroup(P<).Comparedwithpre—treatment,PaO2in—creasedandPaCO2decreasedsignificantlyinthetwogroups(P<),whichismoreobviousinthetreatmentgroup(P<).:chronicobstructivepulmonarydisease;MontelukastSodium慢性阻塞性肺疾病(COPD)是一种可以预防和治疗的疾病,,,参与许多炎性疾病发病过程,(商品名:平奇)辅助治收稿Et期:201102一O1